

ASX RELEASE

7 April 2020

### Shares Subject to Voluntary Escrow to be Released

Pursuant to ASX Listing Rule 3.10A, Amplia Therapeutics Limited (“ATX” or “the Company”) advises the following securities will be released from escrow on 4 May 2020:

Security description	Number
Fully Paid Ordinary Shares	18,460,308

The above securities were originally issued on 4 May 2018 to the vendors of the then privately owned Amplia Therapeutics Pty Ltd as consideration for the acquisition of that company and its Focal Adhesion Kinase (FAK) programmes.

Authorised by Dr. John Lambert, CEO and Managing Director.

#### For Further Information

Dr. John Lambert  
CEO and Managing Director  
[john@ampliatx.com](mailto:john@ampliatx.com)  
[www.ampliatx.com](http://www.ampliatx.com)

#### About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).